Objective: There is controversy about the clinical consequences of intermediate alleles (IAs) in Huntington Disease (HD). The main objective of this study was to establish the clinical manifestations of IA carriers for a prospective, international, European HD registry.

Methods: We assessed a cohort of participants at risk with HTT) gene.

The post Clinical manifestations of Intermediate Allele Carriers in Huntington disease appeared first on Palm Beach Neurological Center.